Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

David Russler-Germain, Hunter Cochran, Fei Wan, Amalia Dubois, Chaz Moreno, Francesca Loyet, Dilan Patel, Brad Kahl, Todd Fehniger, Amanda Cashen, Armin Ghobadi, Neha Mehta-Shah, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 5508.

https://doi.org/10.1182/blood-2025-5508

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2025-2129

Published: 2025

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Blood (2025) 146 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2025-3601

Published: 2025

Journal Articles

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin

Blood (2025) 146 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2025-3581

Published: 2025

Journal Articles

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Chan Cheah, Stephen Spurgeon, Sung-Soo Yoon, Melina Boutin, Eva Gonzalez Barca, Krimo Bouabdallah, Ellie John, Tatjana Krautloher, Victoria Otero, Brad Kahl

Blood (2025) 146 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2025-3578

Published: 2025

Journal Articles

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Blood (2025) 146 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2025-1851

Published: 2025

Journal Articles

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Blood (2025) 146 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2025-6324

Published: 2025

Journal Articles

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Blood (2025) 146 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2025-6312

Published: 2025

Journal Articles

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

Amber Williams, Kristen Rosenthal, Stephen Ansell, Ian Flinn, Brad Kahl, Tycel Phillips, Julie Vose, Timothy Quill

Blood (2025) 146 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2025-4650

Published: 2025

Journal Articles

Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Chijioke Nze, Clark Andersen, Matthew Maurer, Melissa Larson, Jean Koff, Jonathon Cohen, Thomas Habermann, Jonathan Friedberg, Izidore S. Lossos, Peter Martin, Brad Kahl, David Jaye, Andrew Feldman, Carrie Thompson, James Cerhan, Christopher Flowers

Blood (2025) 146 (Supplement 1): 895.

https://doi.org/10.1182/blood-2025-895

Published: 2025

Journal Articles

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Carla Casulo, Hongli Li, Alex Herrera, Sharon Castellino, Sarah Rutherford, Kelly Davison, Angela Punnett, Brad Kahl, John Leonard, Sonali Smith, Joo Song, Kara Kelly, Jonathan Friedberg, Michael Leblanc, Susan Parsons, Angie Mae Rodday, Andrew Evens

Blood (2025) 146 (Supplement 1): 154.

https://doi.org/10.1182/blood-2025-154

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405

Craig Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher Reynolds, Priyank Patel, Michael Robertson, Brad Kahl

Blood (2025) 146 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2025-3574

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826

Blood (2025) 146 (Supplement 1): 351.

https://doi.org/10.1182/blood-2025-351

Published: 2025

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only